Group 1 - VitalHub Corp. will release its financial results for Q4 2025 on March 12, 2026, after market close [1] - A conference call will be held on March 13, 2026, at 9:00 am EST, hosted by CEO Dan Matlow and CFO Brian Goffenberg [1] - The company serves over 1,000 clients globally, focusing on health and human services [2] Group 2 - VitalHub has a two-pronged growth strategy that includes organic growth within its product suite and an aggressive M&A plan [2] - The company is headquartered in Toronto and has over 500 employees worldwide, including a VitalHub Innovations Lab in Sri Lanka [2]

Core Points - VitalHub Corp. has filed a prospectus supplement for a public offering of 5,118,111 common shares at a price of $12.70 per share, aiming for gross proceeds of approximately $65 million, with an additional 767,717 shares available through an over-allotment option for about $9.75 million [1][2][3] Group 1 - The offering is expected to close on or about August 20, 2025, pending regulatory approval from the Toronto Stock Exchange [2] - The common shares will be sold in Canada and may also be offered in the United States under private placement exemptions [3] - The prospectus and its amendments are accessible through SEDAR+, and interested investors can obtain copies from Cormark Securities Inc. [4] Group 2 - VitalHub is a leading software company focused on health and human services, serving over 1,300 clients globally with a product suite that includes electronic health records and operational intelligence [7] - The company has a growth strategy that includes both organic opportunities and an aggressive M&A plan, with a workforce of over 600 employees [7]

Core Points - Vitalhub Corp. held its annual general meeting on June 27, 2025, where all director nominees were elected and MNP LLP was appointed as auditors [1][3] Voting Results - Total shares voted were 33,721,314, representing 60.45% of the total shares issued and outstanding, which is 55,784,972 [1] - Election of Directors: - Barry Tissenbaum received 27,796,480 votes (83.01%) - Roger Dent received 22,227,480 votes (66.38%) - Stephen Garrington received 33,334,105 votes (99.55%) - Dan Matlow received 33,209,025 votes (99.18%) - Francis Shen received 24,660,909 votes (73.65%) - Tony Shen received 27,960,184 votes (83.50%) [2] - Appointment of Auditors: - MNP LLP received 33,564,368 votes (99.53%) for appointment as auditors [4] Company Overview - VitalHub is a leading software company focused on health and human services, offering a product suite that includes electronic health records and operational intelligence [5] - The company serves over 1,000 clients across the UK, Canada, and other regions, and has a growth strategy that includes both organic opportunities and an aggressive M&A plan [5]

Core Viewpoint - VitalHub Corp. has announced a cash acquisition of Induction Healthcare Group PLC, valuing Induction at approximately £9.7 million, with each shareholder entitled to receive £0.10 in cash for each share held [1] Company Overview - Induction provides software solutions that enhance care delivery and patient journeys in hospitals, allowing healthcare providers to deliver care both remotely and face-to-face [3][16] - Key products include Zesty, a patient engagement platform, and Attend Anywhere, a video consultation platform [4][5] Financial Performance - For FY24, Induction reported revenues of £14.4 million, a gross margin of 78.4%, and an adjusted EBITDA loss of £0.3 million [6] - For H1 FY25, revenues were £5.4 million, with a gross margin of 78.2% and an adjusted EBITDA loss of £0.9 million [7] Strategic Rationale - VitalHub views Induction's Zesty platform as complementary to its existing offerings, aiming to enhance product diversity and improve patient outcomes [8] - The acquisition is expected to expand VitalHub's market reach in the UK, Europe, Canada, the Middle East, and Australia [9] - Induction is anticipated to benefit from being part of a larger, well-capitalized enterprise, enabling effective implementation of strategic initiatives [10] Acquisition Details - The acquisition will be executed through a court-approved scheme of arrangement, requiring approval from Induction shareholders and the Court [11][12] - Induction's directors recommend shareholders vote in favor of the scheme, with irrevocable commitments received for approximately 44.3% of Induction's shares [13] - The transaction is expected to close by July 31, 2025, with a long stop date of September 30, 2025 [13]